Organ systems

Cerebral Palsy Alliance Research Foundation Awards Crucial Grants

Retrieved on: 
Monday, January 6, 2020
Health, Neurological disorders, Cerebral Palsy Alliance, Organ systems, Disability, Cerebral palsy, World Cerebral Palsy Day, Spastic cerebral palsy

NEW YORK, Jan. 6, 2020 /PRNewswire-PRWeb/ -- Cerebral Palsy Alliance Foundation (CPARF) is proud to announce the award of nearly $16,000 in funding to its 2019 Small-Grant Cohort.

Key Points: 
  • NEW YORK, Jan. 6, 2020 /PRNewswire-PRWeb/ -- Cerebral Palsy Alliance Foundation (CPARF) is proud to announce the award of nearly $16,000 in funding to its 2019 Small-Grant Cohort.
  • The winning grants fund critical researcher training, equipment, and travel to several underserved nations to help treat people with cerebral palsy (CP) and assist their families.
  • CPARF funds research that will change the lives of people with CP, a disability that affects 18 million people globally.
  • Cerebral Palsy Alliance Research Foundation won't stop until people with CP can live pain-free, until they can live the lives they envision for themselves, and until they can express what's on their mind and be understood even when they can't communicate verbally.

FDA approves Fiasp® for treatment of children with diabetes

Retrieved on: 
Monday, January 6, 2020
Organ systems, RTT, Endocrine system, Medicine, Eli Lilly and Company, Diabetes, Insulin, Type 1 diabetes, Insulin pump, Diabetes management

"Children can be unpredictable and having the option of a fast-acting insulin that doesn't require pre-meal dosing like Fiasp is a welcome development for the diabetes community."

Key Points: 
  • "Children can be unpredictable and having the option of a fast-acting insulin that doesn't require pre-meal dosing like Fiasp is a welcome development for the diabetes community."
  • The approval is based on the FDA's review of data from the onset 7 clinical trial, which confirmed the efficacy and safety of Fiasp in children.
  • Fiaspis a man-made insulin used to control high blood sugar in adults and children with diabetes mellitus.
  • Streisand R andMonaghan M. Youngchildren with type 1 diabetes: Challenges, research, and future directions.Current Diabetes Reports2014; 14(9): 520:
    Wysocki T,et al.

Tauriga Sciences Inc. Showcases Graphic Design for the Retail Display Box of its CBG Infused Tauri-Gum Version

Retrieved on: 
Monday, January 6, 2020
Drugs, Communication, Forward-looking statement, CBD, Chewing gum, Government procurement in the United States, Cannabidiol, Organ systems

Tauriga Sciences, Inc. (TAUG) is a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities.

Key Points: 
  • Tauriga Sciences, Inc. (TAUG) is a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities.
  • One such opportunity on which the Company has acted, involves the Company having entered into the cannabidiol (or CBD) infused chewing gum product business, as more fully described above and in prior press releases.
  • Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances.
  • You should not place undue reliance on these forward-looking statements.

Acucela Announces Publication Assessing the Role of Emixustat Hydrochloride in Retinal Degeneration Treatment

Retrieved on: 
Monday, January 6, 2020
Pharmaceutical, Optical, Health, Clinical trials, Ophthalmology, Organ systems, Vision, Diabetes, Blindness, Retinopathy, Emixustat, Diabetic retinopathy, Stargardt disease, Retina, Draft:Adeno associated virus and gene therapy of the human retina, Gene therapy of the human retina, Emixustat Hydrochloride, Acucela Inc.

Authors of the paper explored the cellular and metabolic stressors associated with degenerative retinal diseases and the potential role of visual cycle modulation with emixustat in the treatment of these diseases.

Key Points: 
  • Authors of the paper explored the cellular and metabolic stressors associated with degenerative retinal diseases and the potential role of visual cycle modulation with emixustat in the treatment of these diseases.
  • The accumulation of toxic visual cycle byproducts and retinal hypoxia are stressors associated with retinal diseases such Stargardt disease (STGD) and diabetic retinopathy (DR), respectively.
  • Emixustats mechanisms of action and preclinical data supporting the role of emixustat in the treatment of these diseases is detailed.
  • This publication supports the rationale for investigating emixustat in the treatment of Stargardt disease and diabetic retinopathy.

Equilibrium Nutrition Releases First-Ever DAY & NIGHT Five-Factor Metabolic Supplement and Nutrition Plan, Fatlossity™

Retrieved on: 
Monday, January 6, 2020
Branches of biology, Articles, Organ systems, Physiology, Thermogenesis, Cortisol, Metabolism, Thermogenics, Nutrition, Stress, Sleep

BOSTON, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Equilibrium Nutrition announced today the launch of a groundbreaking DAY & NIGHT supplement and nutrition plan, Fatlossity .

Key Points: 
  • BOSTON, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Equilibrium Nutrition announced today the launch of a groundbreaking DAY & NIGHT supplement and nutrition plan, Fatlossity .
  • The first of its kind, Fatlossity regulates five key metabolic factors: Thermogenesis, Hormonal Balance, Blood Sugar Support, Stress and Cortisol, and Sleep and Recovery.
  • Fatlossity also contains ancient Ayurvedic herbs, known for their balancing capabilities and thermogenic properties, which can boost metabolism and increase fat burning.
  • Fatlossity is the first-ever DAY & NIGHT metabolic supplement developed to help people struggling to lose weight and keep it off.

Flora Growth Launches “Flora Beauty”

Retrieved on: 
Monday, January 6, 2020
Skin care, Drugs, Organ systems, Medical specialties, Cosmetics, Cannabidiol, Cannabis, Cleanser

TORONTO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Flora Growth Corp. (Flora or the Company) is pleased to announce that it has launched a beauty and cosmetics division called Flora Beauty.

Key Points: 
  • TORONTO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Flora Growth Corp. (Flora or the Company) is pleased to announce that it has launched a beauty and cosmetics division called Flora Beauty.
  • Flora Beauty will produce nine different beauty and cosmetics products using Floras organic CBD oil under two beauty brands.
  • ELEMENTS will have moisturizing products for the face, cleansers, masks and eye contour, including:
    All of Flora Beautys products will be organic, including CBD and cruelty free.
  • At Flora, we are building the worlds largest and lowest cost vertically-integrated producer of organic cannabis oils, CBD-infused food & beverage, pharmaceutical-grade, medical and cosmetic-grade derivatives from the cannabis plant.

 Clinigen and Orphazyme launch an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C

Retrieved on: 
Monday, January 6, 2020
Health, FDA, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Rare diseases, Lipid storage disorders, Organ systems, Health, Medicine, Niemann–Pick disease, type C, Niemann–Pick disease, Niemann, NPC, Gaucher's disease, Type C, Arimoclomol, arimoclomol, NPC, Clinigen Group, Orphazyme A/S

Clinigen Group plc (AIM: CLIN, Clinigen), the global pharmaceutical and services company, has partnered with Orphazyme A/S (ORPHA.CO, Orphazyme), a global biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, to introduce and administer an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C (NPC) in the US.

Key Points: 
  • Clinigen Group plc (AIM: CLIN, Clinigen), the global pharmaceutical and services company, has partnered with Orphazyme A/S (ORPHA.CO, Orphazyme), a global biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, to introduce and administer an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C (NPC) in the US.
  • Orphazyme expects to submit to the FDA for marketing approval of arimoclomol in NPC in H1 2020.
  • Niemann-Pick disease Type C (NPC) is a genetic, progressively debilitating, and often fatal neurovisceral disease.
  • Arimoclomol, the companys lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis.

ProtoKinetix AAGP® Dry Eye Therapy Testing Results

Retrieved on: 
Monday, January 6, 2020
Health, Clinical trials, Research, Science, Pharmaceutical, Optical, Biotechnology, RTT, Organ systems, Ophthalmology, Medical specialties, Autoimmune diseases, Dry eye syndrome, Sjögren syndrome

Based on this ProtoKinetix is shipping AAGP to EyeCRO to commence testing Dry Eye Disease efficacy.

Key Points: 
  • Based on this ProtoKinetix is shipping AAGP to EyeCRO to commence testing Dry Eye Disease efficacy.
  • This testing will involve topical application of AAGP and evaluations of its effects on ocular inflammation.
  • Dry Eye Disease is a condition in which a person does not have enough quality tears to lubricate and nourish the eye.
  • The dry eye disease ophthalmic market is very active, with $7.7 billion in revenues and a current growth of 12.5% CAGR.

Afrezza® (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month

Retrieved on: 
Monday, January 6, 2020
Medicine, Clinical medicine, Organ systems, Eli Lilly and Company, RTT, Dosage forms, Diabetes, Peptide hormones, Inhalable insulin, Insulin, Diabetes management, Inhaler

Biomm intends to commence marketing and distributing Afrezza throughout Brazil, beginning the week of January 13, 2020.

Key Points: 
  • Biomm intends to commence marketing and distributing Afrezza throughout Brazil, beginning the week of January 13, 2020.
  • Available by prescription, Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.
  • Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler.
  • Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute).

Global Neuromodulation Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Boston Scientific Corp. | Technavio

Retrieved on: 
Monday, January 6, 2020
Medical devices, Health, Branches of biology, Neuroscience, Organ systems, Neurophysiology, Neurotechnology, Neuromodulation, Neuropsychology, Pain, Endoscopy, Abbott Laboratories, Pharmaceutical industry in China

In addition, expanding indications are anticipated to boost the growth of the neuromodulation market.

Key Points: 
  • In addition, expanding indications are anticipated to boost the growth of the neuromodulation market.
  • The market is witnessing significant technological advancements related to battery longevity and miniaturization of neuromodulation devices.
  • Major Five Neuromodulation Market Companies:
    Abbott Laboratories operates the business across segments such as Established Pharmaceuticals, Diagnostics, Nutritionals, and Cardiovascular and Neuromodulation.
  • Global Neuroendoscopy Devices Market Global neuroendoscopy devices market by geography (Asia, Europe, North America, and ROW) and product (rigid and semi-rigid endoscopes and flexible endoscopes).